Video

Dr. Morris on the Efficacy of 177Lu-PSMA-617 Plus Best SOC in mCRPC

Michael J. Morris, MD, discusses the efficacy of Lutetium 177 PSMA-617 as a treatment for patients with metastatic castration-resistant prostate cancer.

Michael J. Morris, MD, medical oncologist, section head, Prostate Cancer, GU Oncology, Memorial Sloan Kettering Cancer Center, discusses the efficacy of Lutetium 177 (177Lu) PSMA-617 (177Lu-PSMA-617) as a treatment for patients with metastatic castration-resistant prostate cancer (mCRPC).

The phase 3 VISION trial (NCT03511664), which examined the addition of 177Lu-PSMA-617 to best standard-of-care therapy in patients with mCRPC, showed that the agent is safe and can prolong survival in a paradigm where few other therapeutic options are available, according to Morris. Additionally, quality-of-life data will soon read out and complement data already reported on other clinical end points of the study, Morris adds.

In addition to overall survival and radiographic progression-free survival, another important end point was time to first symptomatic skeletal event (SSE). The risk of SSEs was reduced by 50%. In the past, findings like this have been known to serve as the basis for the approval of other therapeutics in prostate cancer, Morris notes. Moreover, the prostate-specific antigen decline rate and the overall response rate were higher in the 177Lu-PSMA-617 arm vs the control arm. Collectively, data from the trial suggest that 177Lu-PSMA-617 plus standard-of-care therapy is superior to standard-of-care therapy alone for this patient population, Morris concludes.

Clinicians referring a patient to MSK can do so by visiting msk.org/refer, emailing referapatient@mskcc.org, or by calling 833-315-2722.
Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD